Loading
Computed Tomography / Lung Non Small Cell Carcinoma / Stage IIIA Lung Cancer AJCC V8 · Phase 3 Trial
ClinicalTrials.gov · August 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registered Phase 3 randomized trial comparing ceralasertib (AZD6738) plus durvalumab versus durvalumab alone in patients with stage II–IIIB resected non-small cell lung cancer. No efficacy or safety results are available from this registry record; the study is currently active but not recruiting.
Phase 3, Interventional, Randomized, Parallel, Open label, Treatment purpose. Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8; age from 18 Years. Intervention: Arm B (Durvalumab and AZD6738). Compared with: Arm A (Durvalumab) — Active Comparator. n = 630. 192 sites: United States.
This is a registered Phase 3 randomized trial comparing ceralasertib (AZD6738) plus durvalumab versus durvalumab alone in patients with stage II–IIIB resected non-small cell lung cancer. No efficacy or safety results are available from this registry record; the study is currently active but not recruiting.
No efficacy, safety, or outcome data are reported.
The source did not state who this applies to in practice.
This is a Phase 3 trial registration with no results posted; the study is active but not yet recruiting and outcome data are not available.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06732401). This is a study registration, not published results. Lead sponsor: National Cancer Institute (NCI). Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 630 participants (ESTIMATED). Conditions: Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8. Interventions: PROCEDURE: Biospecimen Collection; DRUG: Ceralasertib; PROCEDURE: Computed Tomography; BIOLOGICAL: Durvalumab; PROCEDURE: Echocardiography Test. Primary outcome measures: Disease free survival (DFS) , From randomization to the earliest event defined as the first recurrence of non-small cell lung cancer (NSCLC), any new lung cancer or death, up to 10 years. Brief summary: This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.